Bio-Rad Laboratories Files 8-K on Financials
Ticker: BIO-B · Form: 8-K · Filed: May 7, 2024 · CIK: 12208
| Field | Detail |
|---|---|
| Company | Bio-Rad Laboratories, Inc. (BIO-B) |
| Form Type | 8-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: BIO
TL;DR
BIO-RAD filed an 8-K on May 7th for financial updates. Keep an eye on their numbers.
AI Summary
Bio-Rad Laboratories, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending May 7, 2024. No specific financial figures or operational details were provided in the excerpt.
Why It Matters
This filing indicates Bio-Rad Laboratories is providing an update on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediate negative news or significant changes.
Key Players & Entities
- BIO-RAD LABORATORIES, INC. (company) — Registrant
- May 7, 2024 (date) — Date of Report
- 1000 Alfred Nobel Dr. Hercules , California 94547 (address) — Principal executive offices
- 001-07928 (filing_number) — Commission File Number
FAQ
What specific financial results are being reported by Bio-Rad Laboratories?
The provided excerpt states the filing is for 'Results of Operations and Financial Condition' but does not detail specific financial figures.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is May 7, 2024.
What is Bio-Rad Laboratories' principal executive office address?
The principal executive offices are located at 1000 Alfred Nobel Dr. Hercules, California 94547.
What is the Commission File Number for Bio-Rad Laboratories?
The Commission File Number is 001-07928.
What type of SEC filing is this and what section of the Securities Exchange Act does it comply with?
This is a CURRENT REPORT (8-K) filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-07 16:18:26
Key Financial Figures
- $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
Filing Documents
- bio-20240507.htm (8-K) — 35KB
- bio-8k572024xex991.htm (EX-99.1) — 319KB
- 0000012208-24-000036.txt ( ) — 537KB
- bio-20240507.xsd (EX-101.SCH) — 3KB
- bio-20240507_def.xml (EX-101.DEF) — 15KB
- bio-20240507_lab.xml (EX-101.LAB) — 27KB
- bio-20240507_pre.xml (EX-101.PRE) — 16KB
- bio-20240507_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition On May 7, 2024, Bio-Rad Laboratories, Inc. announced its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits Exhibit Number Description 99.1 Press release of Bio-Rad Laboratories, Inc. dated May 7 , 202 4 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: May 7, 2024 By: /s/ Roop K. Lakkaraju Roop K. Lakkaraju Executive Vice President and Chief Financial Officer